NASDAQ GM
ASPX

Auspex Pharmaceuticals, Inc.

Shareholder Corporation Litigation

Rigrodsky & Long, P.A. Announces Investigation Of Auspex Pharmaceuticals, Inc. (NASDAQ GM: ASPX) Buyout

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Auspex Pharmaceuticals, Inc. (“Auspex” or the “Company”) (NASDAQ GM: ASPX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Teva Pharmaceutical Industries Ltd. (“Teva”) (NYSE: TEVA), in a transaction valued at approximately $3.5 billion.

Under the terms of the agreement, public shareholders of Auspex would receive $101.00 in cash for each share of Auspex they own.

The investigation concerns whether Auspex’s board of directors failed to adequately shop the Company and obtain the best possible value for Auspex’s shareholders before entering into an agreement with Teva.  According to Yahoo! Finance, at least one analyst has issued a price target for Auspex stock at $105.00 per share.

If you own the common stock of Auspex and purchased your shares before March 30, 2015, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to info@rl-legal.com.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.